1. Home
  2. LWLG vs REPL Comparison

LWLG vs REPL Comparison

Compare LWLG & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightwave Logic Inc.

LWLG

Lightwave Logic Inc.

HOLD

Current Price

$16.20

Market Cap

1.9B

Sector

Industrials

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$2.47

Market Cap

692.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LWLG
REPL
Founded
1991
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
692.8M
IPO Year
2011
2018

Fundamental Metrics

Financial Performance
Metric
LWLG
REPL
Price
$16.20
$2.47
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$5.67
AVG Volume (30 Days)
8.3M
10.0M
Earning Date
05-08-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
15.79
5.25
EPS
N/A
N/A
Revenue
$236,855.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
147.74
N/A
52 Week Low
$0.92
$1.50
52 Week High
$15.29
$13.24

Technical Indicators

Market Signals
Indicator
LWLG
REPL
Relative Strength Index (RSI) 70.74 34.70
Support Level $3.19 $1.50
Resistance Level N/A $2.96
Average True Range (ATR) 1.90 0.30
MACD 0.04 0.11
Stochastic Oscillator 83.88 61.63

Price Performance

Historical Comparison
LWLG
REPL

About LWLG Lightwave Logic Inc.

Lightwave Logic Inc is a specialty materials and intellectual property company focused on the development and commercialization of proprietary electro-optic (EO) polymer materials designed to enable high-speed optical modulators for data communications and other photonic applications. Its Perkinamine family of EO polymers is designed for integration into silicon photonics (SiPh) and other photonic integrated circuit (PIC) platforms, supporting high-speed optical modulation with lower drive voltage requirements compared with some conventional silicon-based and III-V compound semiconductor approaches. The company operates as a single reportable segment.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: